The Frankfurt Foundation Quality of Medicines is led by a three-person honorary executive board of directors. Board members are both founders, Prof. Henning Blume, PhD and Dagmar Walluf-Blume, PhD as well as the current President of the German Pharmaceutical Society (DPhG), Prof. Dagmar Fischer, PhD.
Prof. Dr. Dr. h.c. Henning Blume
Chairman of the executive board
Henning Blume studied pharmacy at the Goethe University in Frankfurt. After receiving his PhD and completion of postdoctoral research he was appointed Extraordinary Professor at Frankfurt University.
Professor Blume was head of the Central Laboratory of German Pharmacists for 15 years and started own business activities by establishing the Clinical Research Organisation (CRO) SocraTec R&D, Ltd, in 1997.
His fields of research include biopharmaceutical and pharmacokinetic investigations, with particular focus on the characterisation of bioavailability and bioequivalence of drug products, and the development of therapy-optimised medicinal products containing already established active ingredients. He published more than 230 research papers.
Henning Blume is member of important international scientific associations on the fields of biopharmaceutics and clinical pharmacology and served as appointed expert in numerous scientific committees, e.g. the Bioavailability Commission of the German Authorities and the German Pharmacopeia as well as the Expert Network at the European Medicines Agency (EMA). For more than a decade he was president of the Section for Official Laboratories and Medicines Control Services of the International Pharmaceutical Federation (FIP), and chairman of the FIP Special Interest Group on Bioavailability and Bioequivalence. Moreover he is elected chairman of the European Network on Bioavailability and Biopharmaceutics and started the Global Bioequivalence Harmonisation Initiative.
Henning Blume received the EUFEPS Ouroboros Award, the German Generics Award and the Honorary Award of the German Pain Award as well as the Elsa-Ullmann Medal. He is Honorary Member of the Argentinian Diabetes Association and was awarded as „Doctor honoris causa“ by the Semmelweis University, Budapest/Hungary.
Prof. Dr. Dagmar Fischer
Member of the executive board
Professor Dr. Dagmar Fischer studied Pharmacy at the University Würzburg and received her diploma, PhD and Habilitation at the Philipps University Marburg. She completed several research stays, e.g. at the Texas Tech Health Sciences Center in Amarillo, TX, USA.
After several years as Head of Preclinical Research and Development in the pharmaceutical industry, she joined from 2008 to 2020 the Friedrich-Schiller University as full professor for pharmaceutical technology and biopharmacy. Since 2020 Prof. Fischer is heading the chair of pharmaceutical technology at the Friedrich-Alexander University Erlangen-Nürnberg.
Her research is focussed on innovative nanoparticulate drug delivery systems in the field of infection, inflammation and aging including the development of new test systems according to the 3R concept als alternatives to animal experiments for nanosafety testings. Her research was awarded with several awards such as the the PHOENIX Pharmaceutics Science Award.
Dagmar Fischer ia the member of many boards in societies and institutes. Actually she is the president of the German Pharmaceutical Society (DPhG).
Dr. Dagmar Walluf-Blume
Deputy chairwoman of the executive board
Dr. Dagmar Walluf-Blume studied pharmacy at the Johann Wolfgang Goethe University in Frankfurt am Main and received her PhD in pharmaceutical chemistry. She is a specialized pharmacist for drug information.
In 1985 she joined Stada Arzneimittel AG, Bad Vilbel, where she worked in clinical research and the medical-scientific department. Dr. Walluf-Blume moved to the Federal Association of the Pharmaceutical Industry (BPI) in Frankfurt and headed the „Research and Development“ and „Self-Medication“ departments. In 2002 she switched to Takeda Pharma GmbH in Aachen, where she set up and headed the Health Policy and Governmental Affairs department.
Currently, Dr. Walluf-Blume works at SocraTec C&S GmbH, Oberursel, which deals with clinical trials, concepts and strategies in drug development and drug approval.